Who Paid My Doc
Pamela Moalli
Urogynecology and Reconstructive Pelvic Surgery Pittsburgh, PA Medical Doctor
NPI 1912971672 CMS profile 1300372
300 Halket St, Suite 0610, Pittsburgh, PA 15213
General payments
$10,238
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$61,317
Through program year 2023, Pamela Moalli of Pittsburgh, PA is reported in the CMS Open Payments database as having received $10,238 across 5 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $61,317 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 80th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $28 | 1 | |
| 2020 | General | $10,211 | 4 |
Beside peers
- Pamela Moalli
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Pamela Moalli were reported at $0. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.
Show as a table
| Year | Pamela Moalli | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $358 | $132–$1,270 | $163 |
| 2020 | $10,211 | $198 | $86–$642 | $114 |
| 2021 | $0 | $361 | $118–$1,182 | $132 |
| 2022 | $0 | $410 | $128–$1,175 | $149 |
| 2023 | $28 | $434 | $152–$1,344 | $160 |
| 2024 | $0 | $494 | $193–$1,331 | $164 |
| 2025 | $0 | $412 | $133–$1,300 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
1,078
Drug cost
$243,890
Branded share of claims
43.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 163 | $110,445 | |
| Mirabegron Er Mirabegron | Brand | 56 | $25,839 | |
| Premarin Estrogens, Conjugated | Brand | 54 | $23,491 | |
| Estradiol | Generic | 293 | $23,332 | |
| Gemtesa Vibegron | Brand | 35 | $22,875 | |
| Methenamine Hippurate | Generic | 214 | $14,983 | |
| Trospium Chloride Er Trospium Chloride | Brand | 69 | $12,992 | |
| Estring Estradiol | Brand | 11 | $5,578 | |
| Desonide | Generic | 11 | $1,387 | |
| Trospium Chloride | Generic | 33 | $1,110 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 36 billing codesPaid by Medicare
$32,804
Medicare patients
139
Services billed
277
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 68% | |
| Arthritis | 62% | |
| Osteoporosis | 27% | |
| Depression | 24% | |
| Cancer | 19% | |
| Chronic kidney disease | 17% | |
| Diabetes | 16% | |
| Ischemic heart disease | 13% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in Pennsylvania
Vincent Lucente
Urogynecology and Reconstructive Pelvic Surgery · Allentown, PA
Miles Murphy
Urogynecology and Reconstructive Pelvic Surgery · Allentown, PA
Michael Bonidie
Urogynecology and Reconstructive Pelvic Surgery · Mechanicsburg, PA
Lily Arya
Urogynecology and Reconstructive Pelvic Surgery · Philadelphia, PA
Julie Drolet
Urogynecology and Reconstructive Pelvic Surgery · York, PA
Alexander Bruscke
Urogynecology and Reconstructive Pelvic Surgery · Quakertown, PA
Related records
Urogynecology and Reconstructive Pelvic Surgery in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.